PLEASANTON, California, March 31, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Cytomegalovirus (CMV) test(1) is now commercially available in Europe. CMV viral load testing helps physicians manage immunocompromised patients at risk of CMV disease, including those who have undergone solid organ and stem cell transplantation. This standardized and fully automated test monitors CMV infections using an easy-to-operate system capable of delivering accurate and reliable results to clinicians so that they can make critical treatment decisions.

"We are pleased to offer this innovative test to address a key medical need for immunosuppressed patients," said Paul Brown, Ph.D., Head of Roche Molecular Diagnostics. "With this test, Roche now enables rapid, standardized CMV testing while improving workflow for laboratories."